fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjects

fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjects - fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjects

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004381

Enrollment

Registered

2010-10-14

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance-related disorders, Mood disorders, Anxiety disorders

Interventions

1day 1 time Aprepitant 125mg washout duration 1 week 1day 1 time placebo (lactose) 1day 1 time placebo (lactose) washout duration 1 week 1day 1 time Aprepitant 125mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: healthy adult

Exclusion criteria

Exclusion criteria: patients with psychiatric disorder patients with hepatic, kidney, cardiac disorders patients taking other drugs

Design outcomes

Primary

Measure	Time frame
Comparison between placebo and Aprepitant conditions.	—

Countries

Japan

Contacts

Public ContactYumiko Ikeda

Nippon Medical School Pharmacology

y-ikeda@nms.ac.jp03-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026